{"type":"trials","record":{"id":34052,"source_id":"clinicaltrials-gov","external_id":"NCT04407390","title":"Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly","brief_summary":"The purpose of this study is to investigate whether nicotinamide riboside supplementation can attenuate the severity of SARS-CoV-2 infections in elderly patients. A major event in aging is the loss of the central metabolite nicotinamide adenine dinucleotide (NAD+) that appear to be important in the proinflammatory environment that occur during aging. Notably, recent work from our and other groups suggest that aging can be ameliorated by even a short-term treatment of the NAD+ precursor nicotinamide riboside. Nicotinamide riboside has recently been shown to be able to return aging tissues to a younger state even after short term treatment. This vitamin B3- analog is naturally occurring, is readily taken up through oral administration and has been tested in human trials with few side effects. In this randomized double blinded case-control trial, the investigators will treat elderly (\\>70 year old) COVID19 patients with 1 g of nicotinamide riboside (NR-E) or placebo for 2 weeks and investigate if this affects the clinical course of the disease.","overall_status":"Withdrawn","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"University of Copenhagen","enrollment":0,"countries":["Denmark"],"start_date":"2020-06-01","completion_date":"2022-05-01","last_update_date":"2022-09-22","source_url":"https://clinicaltrials.gov/study/NCT04407390","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:20:13.198107+00:00","last_seen_at":"2026-09-25T06:05:47.306+00:00","metadata":{"sex":"ALL","acronym":"NR-COVID19","age_range":"70 Years","comparator":"Control","organization":"University of Copenhagen","interventions":["Nicotinamide riboside","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Hypoxic respiratory failure — Day 1","Hypoxic respiratory failure — Day 7","Hypoxic respiratory failure — Day 14","Hypoxic respiratory failure — Day 90","Mortality — Day 1","Mortality — Day 7","Mortality — Day 14","Mortality — Day 90","Sepsis — Day 1","Sepsis — Day 7","Sepsis — Day 14","Sepsis — Day 90","Circulatory failure — Day 1","Circulatory failure — Day 7","Circulatory failure — Day 14","Circulatory failure — Day 90","Days in hospital — Day 1","Days in hospital — Day 7","Days in hospital — Day 14","Days in hospital — Day 90"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["COVID","Nicotinamide riboside","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: nicotinamide riboside.","quality_checked_at":"2026-09-25T06:05:48.394941+00:00","duplicate_cluster_key":"id:nct04407390","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-06-01 to 2022-05-01","comparator":"Control","confidence":"structured-source","population":"ALL · 70 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:05:47.316Z","intervention":["Nicotinamide riboside","Placebo"],"participants":0,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Hypoxic respiratory failure — Day 1","Hypoxic respiratory failure — Day 7","Hypoxic respiratory failure — Day 14","Hypoxic respiratory failure — Day 90","Mortality — Day 1","Mortality — Day 7","Mortality — Day 14","Mortality — Day 90","Sepsis — Day 1","Sepsis — Day 7","Sepsis — Day 14","Sepsis — Day 90","Circulatory failure — Day 1","Circulatory failure — Day 7","Circulatory failure — Day 14","Circulatory failure — Day 90","Days in hospital — Day 1","Days in hospital — Day 7","Days in hospital — Day 14","Days in hospital — Day 90"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"nad-metabolism","is_published":true,"match_reasons":["Title contains controlled term: nicotinamide riboside.","Abstract contains controlled term: nad+, nicotinamide riboside.","Source terminology contains: nicotinamide riboside.","Title supplies longevity context: elderly.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"NAD metabolism","slug":"nad-metabolism"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/34052","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}